HAE's real opportunity isn't switching lanadelumab patients, it's reaching the 1,500 to 2,500 UK patients who qualify for prophylaxis but have never received it.

Lanadelumab (Takhzyro, Takeda) is NHS England's commissioned HAE prophylaxis standard via NICE TA606, delivered subcutaneously and priced with a confidential PAS estimated at 50 to 60% off a roughly £45,000-a-year UK WAC. It is entrenched at NHS specialist HAE centres in Sheffield, Cambridge, Birmingham, London, and Manchester, which manage over 90% of UK HAE patients. But entrenchment is not saturation: of an estimated 5,000-6,000 UK HAE patients, only 1,500-2,000 are on prophylaxis. Between 1,500 and 2,500 attack-active patients, three or more attacks a year, have never been prophylaxed, held back less by clinical eligibility than by NHS specialist-centre capacity and an 8 to 10 year mean diagnostic delay, one of the longest in the developed world.

For a new oral prophylaxis entrant, growing the market is the more tractable strategy than displacing lanadelumab in stable patients, mirroring how berotralstat (Orladeyo, BioCryst) entered the US. Berotralstat already cleared NICE as TA738 in 2021 and has held the UK's first and only oral-prophylaxis slot for nearly five years. Donidalorsen (Ionis Pharmaceuticals), an antisense oligonucleotide dosed subcutaneously, reported an 81% attack-rate reduction in the Phase 3 OASIS-HAE trial and is expected to file with the MHRA in 2024-2025, putting a clinically strong competitor on a collision course with any new entrant targeting the injectable segment. NICE's HAE pathway is standard technology appraisal, applying the ordinary £20,000-30,000 per QALY threshold that lanadelumab needed a 50-60% PAS to clear.

Donidalorsen's strong Phase 3 data puts a fast-moving competitor on a collision course.

Five questions this report answers:

Q1 - Where does lanadelumab's NHS entrenchment leave room, switching patients or growing the market?

Q2 - How large is the UK's never-prophylaxed HAE population before MHRA approval?

Q3 - What is the donidalorsen competitive timeline and WAC/PAS design that clears NICE's bar?

Q4 - What deliverable formats come with a commissioned HAE launch readiness assessment?

Q5 - What must a pre-launch HAE prophylaxis asset prove to succeed in the UK?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#HAE #HereditaryAngioedema #NICE #UKMarketAccess #RareDisease #LaunchReadiness

Live report page:  https://axlrx.ai/hereditary-angioedema/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-   hello@axlrx.ai

Web-   https://axlrx.ai/